EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Childhood cancer in Sweden during the COVID-19 pandemic: Temporal patterns in incidence and survival in a nationwide register-based cohort study

Christina-Evmorfia Kampitsi iD, Javier Louro iD, Hanna Mogensen iD, Friederike Erdmann, Kleopatra Georgantzi iD, Mats Heyman iD, Päivi Lähteenmäki iD, Anna Nilsson, Maria Feychting iD, Giorgio Tettamanti iD

PLOS Medicine · 2026

DOI: 10.1371/journal.pmed.1004934 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift PLOS Medicine, 2026. Verfasst von Christina-Evmorfia Kampitsi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: COVID-19, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Barncancerfonden, VetenskapsrÃ¥det.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The COVID-19 pandemic raised concerns about diagnostic delays and treatment disruptions in childhood cancer, potentially threatening survival. We assessed childhood cancer incidence and survival in Sweden, where only few restrictions were implemented, during the pandemic period. Methods and findings We conducted a nationwide, register-based cohort study including all children and adolescents (0–19 years) with a new cancer diagnosis, defined according to the International Classification of Childhood Cancer, Third Edition (ICCC-3), reported to the Swedish National Cancer Register during 2015–2022 ( N = 3,333; 2,069 pre-pandemic and 1,264 during the pandemic). We compared quarter-specific age-standardized incidence rates (ASR) per 1,000,000 (overall and by diagnostic group) during 2020–2022 to the 2015–2019 average. Overall survival at 3, 6, and 12 months post-diagnosis was calculated using the Kaplan–Meier estimator, and mortality at the same intervals was assessed with logistic regression, adjusted for age at diagnosis, sex, and maternal education. Overall incidence rates remained largely stable during the pandemic (ASR 2015–2019 : 179.5; 95% CI [172.9,186.1], ASR 2020 : 174.7; 95% CI [160.5,189.0], ASR 2021 : 176.5; 95% CI [161.6,191.5], ASR 2022 : 181.2; 95% CI [166.3,196.2]), but diagnostic groups showed differing tendencies. Acute lymphoblastic leukemia (ALL) declined from February 2020, followed by a rebound in 2021. Acute myeloid leukemia (AML) declined throughout 2020–2022 without evidence of a rebound. Lymphomas declined in mid-2020 before returning to pre-pandemic levels. Central nervous system (CNS) tumors transiently increased in 2020. Overall 1-year survival was 94.8% (95% CI [93.9,95.8]) in the pre-pandemic period and 95.9% (95% CI [94.8,97.0]) during the pandemic. No increase in 6-month or 1-year mortality was observed; if anything, point estimates suggested lower 1-year mortality for ALL (aOR = 0.37; 95% CI [0.08,1.21]; p = 0.14) and CNS tumors (aOR = 0.61; 95% CI [0.31,1.14]; p = 0.13). The main limitation of this study was statistical uncertainty for certain diagnostic groups due to small case numbers.

Conclusions

Overall childhood cancer incidence and survival in Sweden showed no major changes during the COVID-19 pandemic. Fluctuations in diagnostic-group-specific incidence may reflect delayed diagnoses or shifts in disease triggers; however, the timing of the ALL decline and the lack of AML rebound challenge this interpretation. Stable or improved survival suggests that any disruptions were not associated with poorer survival up to 1 year after diagnosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19NeoplasmsHumansSwedenIncidenceFemaleInfantChild, PreschoolMaleAdolescentRegistriesChildInfant, NewbornCohort StudiesYoung AdultSARS-CoV-2PandemicsTime Factors

Autor:innen und Institutionen

  • Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Department of Immunology, Genetics and Pathology, Cancer Precision Medicine, Uppsala University, Uppsala, Sweden.
  • Research Group Aetiology and Inequalities in Childhood Cancer, Division of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johann…
  • Department of Prevention and Evaluation, Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany.
  • Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

ORCID-Profile: Christina-Evmorfia Kampitsi, Javier Louro, Hanna Mogensen, Kleopatra Georgantzi, Mats Heyman, Päivi Lähteenmäki, Maria Feychting, Giorgio Tettamanti

Förderung

  • Barncancerfonden
  • VetenskapsrÃ¥det

Zitieren

APA

Kampitsi, C. E., Louro, J., Mogensen, H., Erdmann, F., Georgantzi, K., Heyman, M., Lähteenmäki, P., Nilsson, A., Feychting, M., & Tettamanti, G. (2026). Childhood cancer in Sweden during the COVID-19 pandemic: Temporal patterns in incidence and survival in a nationwide register-based cohort study. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1004934

Vancouver

Kampitsi CE, Louro J, Mogensen H, Erdmann F, Georgantzi K, Heyman M, et al. Childhood cancer in Sweden during the COVID-19 pandemic: Temporal patterns in incidence and survival in a nationwide register-based cohort study. PLOS Medicine. 2026. doi:10.1371/journal.pmed.1004934

BibTeX
@article{Kampitsi2026,
  author = {Kampitsi, Christina-Evmorfia and Louro, Javier and Mogensen, Hanna and Erdmann, Friederike and Georgantzi, Kleopatra and Heyman, Mats and Lähteenmäki, Päivi and Nilsson, Anna and Feychting, Maria and Tettamanti, Giorgio},
  title = {Childhood cancer in Sweden during the COVID-19 pandemic: Temporal patterns in incidence and survival in a nationwide register-based cohort study},
  journal = {PLOS Medicine},
  year = {2026},
  doi = {10.1371/journal.pmed.1004934}
}
Kostenlos starten →